No black box warning on record for Rezlidhia

As of the latest FDA labeling reviewed, Rezlidhia (OLUTASIDENIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Rezlidhia medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Monitor liver function tests during treatment with REZLIDHIA. If hepatotoxicity occurs, interrupt and reduce or discontinue REZLIDHIA. ( 2.3 , 5.2 ) 5.1 Differentiation Syndrome REZLIDHIA can cause differentiation syndrome. In the clinical trial of REZLIDHIA in patients with relapsed or refractory AML, differentiation syndrome occurred in 16% (25/153) of

No black box warning on record for Rezlidhia

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Monitor liver function tests during treatment with REZLIDHIA. If hepatotoxicity occurs, interrupt and reduce or discontinue REZLIDHIA. ( 2.3 , 5.2 ) 5.1 Differentiation Syndrome REZLIDHIA can cause differentiation syndrome. In the clinical trial of REZLIDHIA in patients with relapsed or refractory AML, differentiation syndrome occurred in 16% (25/153) of

Rezlidhia Black Box Warning

No black box warning on record for Rezlidhia

Other warnings & precautions

Rezlidhia Black Box Warning

No black box warning on record for Rezlidhia

Other warnings & precautions